Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Hyaluronate Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 1765-A

    Specialty Guideline Management Hyaluronates

    Customize your policy alerts

    Sign up for cvs_caremark Policy 1765-A alerts

    Get alerted when Policy 1765-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for listed hyaluronate products used to treat pain from osteoarthritis of the knee when diagnostic, treatment history, clinical symptom, and continuation criteria are met.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Hyaluronates
    Policy CodePolicy 1765-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests only after documenting diagnostic support, functionally interfering knee pain, and inadequate response or intolerance to required treatment trials.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    17Hyaluronate products referenced
    12 monthsInitial authorization period
    5 of 9Clinical signs and symptoms required without radiographic evidence
    3 monthsAnalgesic trial duration
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Interval between injection series

    Coverage Criteria

    Initial Therapy Criteria

    Covered for knee osteoarthritis when all of the following criteria are met.

    Initial therapy for knee osteoarthritis

    • Diagnostic support

      • Radiographic evidence of osteoarthritis of the knee is present, such as joint space narrowing, subchondral sclerosis, osteophytes, or subchondral cysts.
      • Clinical signs and symptoms: At least 5 of the specified signs and symptoms are present.5 of 9
    • Functional knee pain: Knee pain interferes with functional activities such as ambulation or prolonged standing.
    • Nonpharmacologic treatment: The member has experienced an inadequate response or adverse effects with nonpharmacologic treatment options such as physical therapy, regular exercise, insoles, knee bracing, or weight reduction.
    • Analgesic treatment: The member has experienced an inadequate response, intolerance, or contraindication to a trial of an analgesic such as acetaminophen up to 3 to 4 grams per day, NSAIDs, or topical capsaicin cream.At least 3 months
    • Intra-articular steroid treatment: The member has experienced an inadequate response, intolerance, or contraindication to a trial of intra-articular steroid injections.At least 3 months
    • Knee replacement timing: The member is not scheduled to undergo total knee replacement within 6 months of starting treatment.Not within 6 months

    Continuation Therapy Criteria

    Covered for continuation when all of the following criteria are met.

    Continuation therapy for knee osteoarthritis

    • Coverage requirements: The member meets all requirements in the coverage criteria.
    • Clinical improvement: The member experienced improvement in pain and functional capacity following the previous injections.
    • Time since prior series: At least 6 months has elapsed since the last injection in the prior completed series of injections.At least 6 months

    Coverage is limited to treatment of pain associated with osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. All other indications are considered experimental/investigational and are not covered as medically necessary.

    All indications other than the covered treatment of pain in osteoarthritis of the knee are considered experimental/investigational and not medically necessary.

    Clinical Thresholds and Required Trials

    Clinical signs and symptoms
    RequirementAt least 5 of the 9 specified signs and symptoms must be present when radiographic evidence is unavailable.
    Diagnostic alternativeClinical signs and symptoms may support the knee osteoarthritis diagnosis instead of radiographic evidence.
    Listed findingsThe specified findings include bony enlargement, bony tenderness, crepitus, low ESR, morning stiffness under 30 minutes, no palpable warmth, age over 50, rheumatoid factor below 1:40, and qualifying synovial fluid findings.
    Erythrocyte sedimentation rate
    ThresholdErythrocyte sedimentation rate must be less than 40 mm/hr.
    Clinical roleA low ESR is one of the specified clinical signs and symptoms supporting the diagnosis.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization — 12 Months

    Prior authorization may be granted for 12 months for treatment of osteoarthritis of the knee when all initial coverage criteria are met.

    • Diagnosis supported by radiographic evidence of knee osteoarthritis or by at least 5 specified signs and symptoms.
    • Knee pain interferes with functional activities, such as ambulation or prolonged standing.
    • Inadequate response or adverse effects with nonpharmacologic treatment options.
    • Inadequate response, intolerance, or contraindication to at least 3 months of analgesic therapy.
    • Inadequate response, intolerance, or contraindication to at least 3 months of intra-articular steroid injections.
    • Total knee replacement is not scheduled within 6 months after treatment starts.
    Prior Authorization

    Continuation Authorization — 12 Months

    Prior authorization may be granted for 12 months for continued treatment of knee osteoarthritis when all continuation requirements are met.

    Policy Background

    Hyaluronates are intra-articular viscosupplementation products used to treat pain associated with osteoarthritis of the knee. This policy addresses coverage and prior authorization for knee osteoarthritis treatment after inadequate response to conservative non-pharmacologic therapy, simple analgesics, and intra-articular steroid injections, when the diagnosis and functional impact support treatment. Continued therapy requires documented improvement after the prior injection series and an appropriate interval between injection series.

    Clinical Definitions

    Crepitus
    TermCrepitus.
    DefinitionA noisy, grating sound on active motion of the joint.
    Clinical roleCrepitus is one of the specified signs and symptoms used to support the knee osteoarthritis diagnosis.
    Low ESR
    TermLow ESR.
    DefinitionAn erythrocyte sedimentation rate below 40 mm/hr.
    Clinical roleLow ESR is one of the specified signs and symptoms used to support the knee osteoarthritis diagnosis.

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial authorization may be granted for 12 months when all of the following criteria are met.

    Initial authorization for hyaluronate treatment of knee osteoarthritis

    • Diagnostic support

      • Radiographic evidence of osteoarthritis of the knee is present, such as joint space narrowing, subchondral sclerosis, osteophytes, or subchondral cysts.
      • Clinical signs and symptoms: At least 5 of the following 9 signs and symptoms are present: bony enlargement, bony tenderness, crepitus on active motion, ESR less than 40 mm/hr, morning stiffness less than 30 minutes, no palpable warmth of synovium, age over 50 years, rheumatoid factor less than 1:40 titer by agglutination method, and clear synovial fluid of normal viscosity with WBC less than 2000/mm3.5 of 9

    Continuation Therapy Criteria

    Continuation Therapy Criteria

    Continuation authorization may be granted for 12 months when all of the following criteria are met.

    Continuation authorization for hyaluronate treatment of knee osteoarthritis

    • Coverage requirements: The member meets all requirements in the coverage criteria.
    • Improvement after previous injections: The member has experienced improvement in pain and functional capacity following the previous injections.
    • Interval between injection series: At least 6 months has elapsed since the last injection in the prior completed series of injections.At least 6 months

    Required Treatment Sequence

    StepRequired trialDurationRequirement for coverage
    1Nonpharmacologic treatment options, such as physical therapy, regular exercise, insoles, knee bracing, or weight reductionNot specifiedInadequate response or adverse effects
    StepRequired trialDurationRequirement for coverage
    2Analgesic such as acetaminophen up to 3 to 4 grams per day, an NSAID, or topical capsaicin creamAt least 3 monthsInadequate response, intolerance, or contraindication
    StepRequired trialDurationRequirement for coverage
    3Intra-articular steroid injectionsAt least 3 monthsInadequate response, intolerance, or contraindication
    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Hyaluronates
    Policy CodePolicy 1765-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests only after documenting diagnostic support, functionally interfering knee pain, and inadequate response or intolerance to required treatment trials.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Required TrialsAuthorization and Documentation RequirementsPolicy BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaRequired Treatment Sequence
    DefinitionLow ESR means an erythrocyte sedimentation rate below 40 mm/hr.
    Morning stiffness
    ThresholdMorning stiffness must be less than 30 minutes.
    Clinical roleMorning stiffness under 30 minutes is one of the specified clinical signs and symptoms.
    Diagnostic contextThis finding may be used among the clinical signs and symptoms supporting knee osteoarthritis when radiographic evidence is unavailable.
    Age
    ThresholdThe member must be over 50 years of age.
    Clinical roleAge over 50 is one of the specified clinical signs and symptoms.
    Diagnostic contextThis finding may be counted toward the required clinical signs and symptoms supporting knee osteoarthritis.
    Rheumatoid factor
    ThresholdRheumatoid factor must be less than a 1:40 titer by the agglutination method.
    Clinical roleThe rheumatoid factor threshold is one of the specified clinical signs and symptoms.
    Diagnostic contextThis finding may be counted among the clinical signs and symptoms supporting the diagnosis.
    Synovial fluid white blood cell count
    ThresholdSynovial fluid white blood cell count must be less than 2000/mm3.
    Fluid findingsThe synovial fluid must be clear and have normal viscosity.
    Clinical roleThese synovial fluid findings are among the specified signs and symptoms supporting the diagnosis.
    Analgesic trial
    Required durationAn analgesic trial must last at least 3 months.
    ExamplesExamples include acetaminophen, nonsteroidal anti-inflammatory drugs, and topical capsaicin cream.
    Response requirementThe member must have an inadequate response, intolerance, or contraindication to the analgesic trial.
    Intra-articular steroid trial
    Required durationA trial of intra-articular steroid injections must last at least 3 months.
    Response requirementThe member must have an inadequate response, intolerance, or contraindication to the steroid injection trial.
    Treatment sequenceThe steroid injection trial is required before authorization for hyaluronate treatment.
    Total knee replacement timing
    Timing requirementTotal knee replacement must not be scheduled within 6 months of starting treatment.
    Coverage conditionThe member must not be scheduled to undergo total knee replacement within the specified period.
    Authorization impactA scheduled knee replacement within 6 months after treatment starts does not meet this coverage criterion.
    Interval between injection series
    Minimum intervalAt least 6 months must have elapsed since the last injection in the prior completed series.
    Treatment phaseThis interval requirement applies to continued treatment.
    Additional continuation requirementContinuation also requires improvement in pain and functional capacity after the previous injections.
    • Member continues to meet all requirements in the coverage criteria.
    • Improvement in pain and functional capacity occurred following the previous injections.
    • At least 6 months has elapsed since the last injection in the prior completed series.
    Documentation Required

    Document Nonpharmacologic Treatment Trial

    Document that the member experienced an inadequate response or adverse effects with nonpharmacologic treatment options before requesting coverage.

    • Examples include physical therapy, regular exercise, insoles, knee bracing, and weight reduction.
    Documentation Required

    Document Analgesic Trial

    Document an inadequate response, intolerance, or contraindication to a trial of analgesic therapy for at least 3 months.

    • Examples include acetaminophen up to 3 to 4 grams per day, NSAIDs, and topical capsaicin cream.
    Documentation Required

    Document Intra-articular Steroid Trial

    Document an inadequate response, intolerance, or contraindication to a trial of intra-articular steroid injections for at least 3 months.

    Denial Risk

    Non-covered Indication

    Requests for indications other than treatment of pain in osteoarthritis of the knee are considered experimental/investigational and not medically necessary.

    • The covered indication is knee osteoarthritis pain in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.
    Denial Risk

    Complete Clinical Criteria

    Coverage may be denied when the clinical documentation does not adequately support knee osteoarthritis.

    • Provide radiographic evidence of knee osteoarthritis, such as joint-space narrowing, subchondral sclerosis, osteophytes, or subchondral cysts; or document at least 5 specified signs and symptoms.
    • Specified signs and symptoms include bony enlargement, bony tenderness, crepitus on active motion, ESR less than 40 mm/hr, morning stiffness of less than 30 minutes, no palpable warmth of synovium, age over 50 years, rheumatoid factor less than 1:40 titer, and qualifying synovial fluid findings.
    • Document knee pain that interferes with functional activities, such as ambulation or prolonged standing.
    Denial Risk

    Upcoming Knee Replacement

    Coverage may be denied when the member is scheduled to undergo a total knee replacement within 6 months of starting treatment.

    Denial Risk

    Continuation Criteria Not Met

    Continuation authorization may be denied when required continuation criteria are not met.

    • No improvement in pain and functional capacity following the previous injections.
    • Fewer than 6 months have elapsed since the last injection in the prior completed series.
    • The member no longer meets all requirements in the coverage criteria.
    Functionally interfering pain: The member has knee pain that interferes with functional activities such as ambulation or prolonged standing.
  1. Nonpharmacologic treatment trial: The member has experienced an inadequate response or adverse effects with nonpharmacologic treatment options such as physical therapy, regular exercise, insoles, knee bracing, or weight reduction.
  2. Analgesic treatment trial: The member has experienced an inadequate response, intolerance, or contraindication to a trial of an analgesic such as acetaminophen up to 3 to 4 grams per day, NSAIDs, or topical capsaicin cream.At least 3 months
  3. Intra-articular steroid treatment trial: The member has experienced an inadequate response, intolerance, or contraindication to a trial of intra-articular steroid injections.At least 3 months
  4. Total knee replacement timing: The member is not scheduled to undergo total knee replacement within 6 months of starting treatment.Not within 6 months of starting treatment